The Robert E. Fitzhenry Vector Laboratory is the first facility of its kind in Canada and one of a few with the capacity to develop and produce viral-vectored vaccines for clinical testing.
Immune memory is an essential component of human survival, enabling the body to more effectively fight off infections that are caused by dangerous pathogens.
The grants, which will support cutting-edge research ranging from the discovery of novel antibiotics to the development of a global vaccination strategy to control Tuberculosis (TB), are part of a larger $667M investment from two of the federal agency’s funding competitions.